Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55414, United States.
J Med Chem. 2024 Jan 11;67(1):65-80. doi: 10.1021/acs.jmedchem.3c01831. Epub 2023 Dec 22.
The discovery and development of small-molecule therapeutics effective against Gram-negative pathogens are highly challenging tasks. Most compounds that are active in biochemical settings fail to exhibit whole-cell activity. The major reason for this lack of activity is the effectiveness of bacterial cell envelopes as permeability barriers. These barriers originate from the nutrient-selective outer membranes, which act synergistically with polyspecific efflux pumps. Guiding principles to enable rational optimization of small molecules for efficient penetration and intracellular accumulation in Gram-negative bacteria would have a transformative impact on the discovery and design of chemical probes and therapeutics. In this Perspective, we draw on inspiration from traditional medicinal chemistry approaches for eukaryotic drug design to present a broader call for action in developing comparable approaches for Gram-negative bacteria.
发现和开发针对革兰氏阴性病原体的小分子治疗药物是极具挑战性的任务。在生化环境中有效的大多数化合物都无法表现出全细胞活性。这种缺乏活性的主要原因是细菌细胞包膜作为渗透屏障的有效性。这些屏障源自营养选择性的外膜,它们与多特异性外排泵协同作用。指导小分子进行合理优化以有效穿透并在革兰氏阴性细菌中积累的原则,将对化学探针和治疗药物的发现和设计产生变革性影响。在本观点中,我们借鉴了针对真核药物设计的传统药物化学方法的灵感,提出了更广泛的行动呼吁,以开发针对革兰氏阴性细菌的类似方法。